Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784977 | 0.93 | MAPK1 (0.59) | MAPK1OPRK1HTR4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1787811 | 0.92 | MAPK1 (0.57) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL463415 | 0.85 | MAPK1 (0.74) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL409818 | 0.79 | MEN1 (0.45) | MAPK1OPRK1MEN1KMT2ARXFP1 | |
| SCHEMBL10144490 | 0.79 | HTR4 (0.61) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL18271231 | 0.79 | PTPN7 (0.56) | MAPK1OPRK1HTR4MEN1KMT2A | |
| SCHEMBL4415420 | 0.78 | MAPK1 (0.55) | MAPK1OPRK1HTR4HPGDSSMYD3 | |
| SCHEMBL2957750 | 0.78 | SMYD3 (0.50) | HTR4MEN1KMT2AHPGDSSMYD3 | |
| SCHEMBL409941 | 0.77 | EPHX1 (0.52) | MEN1KMT2AALDH1A1 | |
| SCHEMBL13880649 | 0.76 | MAPK1 (0.58) | MAPK1OPRK1HTR4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732259-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-9862946-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170198287-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-07-13 | — | — | US | disclosed |
| US-20160376587-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9469664-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20160237426-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-08-18 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9161948-B2 | Peptide oligonucleotide conjugates | SAREPTA THERAPEUTICS, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | SAREPTA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8779128-B2 | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | SAREPTA THERAPEUTICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | AVI BIOPHARMA, INC. (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180223278-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | MAPK1 4567/4885OPRK1 3478/4885HTR4 4580/4885 |
| US-20120065169-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | MAPK1 4345/4885OPRK1 2420/4885HTR4 4373/4885 |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | MAPK1 4567/4885OPRK1 3478/4885HTR4 4580/4885 |
| US-20150073140-A1 | OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS | NSUN2, UPF1, RTCB | MAPK1 4345/4885OPRK1 2420/4885HTR4 4373/4885 |
| US-20160237426-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | MAPK1 4525/4885OPRK1 3165/4885HTR4 4727/4885 |
| US-20120289457-A1 | PEPTIDE OLIGONUCLEOTIDE CONJUGATES | SNRPE, SMN1; SMN2, UPF1 | MAPK1 4525/4885OPRK1 3165/4885HTR4 4727/4885 |
| US-11732259-B2 | Peptide oligonucleotide conjugates | SNRPE, SMN1; SMN2, UPF1 | MAPK1 4525/4885OPRK1 3165/4885HTR4 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.